The Pulmonix team proudly attended the Triad Business Journal “Best Places to Work” gala, where we were recognized as a finalist for one of the Triad’s top workplaces. This honor reflects the collaborative spirit, dedication, and passion that our team brings to advancing rare disease research every day. At Pulmonix, we lead with a patient-first mindset and…
Pulmonix was honored to celebrate Clinical Trials Day alongside Dr. Mary Jo Cagle, CEO of Cone Health. We extend our sincere thanks to Dr. Cagle for her years of support for Pulmonix’s mission and for the fibrosis program at LeBauer Pulmonary Critical Care. Her leadership has been instrumental in advancing clinical research initiatives and improving patient care…
Pulmonix is proud to share that our leadership was recognized as an honoree for the Triad Business Journal’s C-Suite Awards. This event celebrated leadership, innovation, and excellence across the region, highlighting the contributions of executives who drive meaningful change in their organizations and communities. The recognition reflects Pulmonix’s ongoing mission to transform care through cutting-edge clinical…
Real-world studies have reported reduced mortality in patients with idiopathic pulmonary fibrosis (IPF) treated with antifibrotic therapy; however, the initiation or discontinuation of therapy during these studies may have introduced bias. This study investigated the effect of antifibrotic therapy on mortality and other outcomes in patients with IPF using causal inference methodology.